Challenging Cases in Oncology: Managing Opioid-Induced Constipation in Cancer Patients
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: April 30, 2018
Expiration Date: April 30, 2019
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity will consist of a blend of interactive discussions and slide-based presentations which focus on a case study that will exemplify the need to assess for and treat opioid-induced constipation (OIC) in patients with chronic cancer-related pain. The interactive discussion among the panel will provide a comprehensive look at the importance of patient-centered care which focuses on early assessment, ongoing patient communication, and active management of OIC. Oncology practitioners will be introduced to new advances in the treatment of OIC resulting from chronic cancer-related pain.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in identifying and treating opioid-induced constipation.
Upon completion of this educational activity, participants should be able to:
- Explain the pathophysiology and clinical manifestations of opioid-induced bowel dysfunction in patients with chronic, cancer-related pain
- Accurately and effectively assess a patient for constipation relative to opioid therapy
- Design a proactive, individualized management strategy for OIC in patients who are prescribed opioids for pain relative to a prior cancer or its treatments
- Develop a plan for educating cancer patients, their family, and caregivers that will support improved patient engagement, communication, diagnosis, and management of OIC
Challenging Cases in Oncology: Managing Opioid-Induced Constipation in Cancer Patients – Jeffrey A. Gudin, MD; Yvonne D’Arcy, MS, ARNP-C, CNS, FAANP; Jeffrey Fudin, RPh, PharmD, DAIPM, FCCP, FASHP
Instructions for Participation and Credit
This activity is eligible for credit through April 30, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME/CNE/AANP CE (which includes 0.20 pharmacology hours) credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Jeffrey A. Gudin, MD
Pain Management and Palliative Care
Englewood Hospital and Medical Center
Englewood, New Jersey
Dr. Jeff Gudin received his medical degree from Albany Medical College in Albany, New York. He completed his residency in anesthesiology at the Yale University School of Medicine and his fellowship at The Yale Center for Pain Management. While in New Haven, he also trained in addiction medicine and directed a substance abuse treatment center. For the last 18 years, Dr. Gudin has been the Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center. He was previously a Clinical Instructor in Anesthesiology at the Icahn School of Medicine at Mount Sinai. He remains active in teaching and research, and has lectured internationally on a variety of topics in pain management, palliative care, and addiction medicine.
Dr. Gudin is board certified in pain management, anesthesiology, addiction medicine, and hospice and palliative medicine. In addition, he is a medical acupuncturist and a New Jersey State Representative for the American Academy of Pain Medicine. Dr. Gudin has dedicated his career to promoting education in pain management. He attends and has presented at the American Pain Society, American Academy of Pain Management, American Academy of Physical Medicine and Rehabilitation, as well as many other national venues. He serves as a consultant to state medical boards on challenging cases, as well as to industry on novel analgesic products and risk management associated with opioids.
Dr. Gudin is recognized nationally as a leader in pain management. He is an experienced researcher, consultant, speaker, and speaker trainer. He has collaborated with numerous initiatives to enhance responsible prescribing and the safe use of opioid pain medications.
Yvonne D’Arcy, MS, ARNP-C, CNS, FAANP
Yvonne D'Arcy holds a BS and MA in nursing and completed doctoral studies at the University of Maryland and the University of Florida where she also received her Nurse Practitioner Certificate. She holds certification as an adult nurse practitioner (CRNP) and CNS (CS) from the American Nurses Credentialing Center.
Ms. D'Arcy is a member of the American Pain Society and the American Academy of Nurse Practitioners. In addition, she is on the Pain Management News editorial board; The Nurse Practitioner and Nursing editorial advisory boards; is the pain control column editor for Nursing; and pain solutions editor for Journal for Nurse Practitioners. She is also a peer-reviewer for Lippincott Williams and Wilkins and Elsevier Publications. Ms. D'Arcy has published extensively on pain management and palliative care in nursing.
Jeffrey Fudin, RPh, PharmD, DAIPM, FCCP, FASHP
Adjunct Associate Professor of Pharmacy Practice
Albany College of Pharmacy & Health Sciences
Albany, New York
Dr. Jeffrey Fudin received his PharmD from Albany College of Pharmacy and completed rotations in anesthesiology and pain management, ambulatory care, HIV/pharmacotherapy, clinical pharmacy, and oncology. He is an Adjunct Associate Professor of Pharmacy Practice at Albany College of Pharmacy & Health Sciences, Union University. He holds numerous other academic positions including Adjunct Assistant Professor of Pharmacy Practice at the University of Connecticut School of Pharmacy; Adjunct Advanced Practice Clinical Instructor for Advanced Pharmacy Practice, State University of New York College of Pharmacy at Buffalo; Adjunct Advanced Practice Clinical Instructor for Advanced Pharmacy Practice, St. John Fisher College of Pharmacy at Rochester; and Adjunct Instructor for Advanced Pharmacology (NSG 622), SAGE Graduate School of Nursing, Albany. In addition, Dr. Fudin is the Chief Executive Officer & Chief Medical Officer at Remitigate LLC, and Director of PGY2 Pharmacy Pain Residency, and Clinical Pharmacy Specialist, Pain Management, at Samuel Stratton Dept. of Veterans Affairs Medical Center in New York.
Dr. Fudin is a diplomate of the Academy of Integrative Pain Management and the American Academy of Pain Management. He holds memberships in the American Academy of Pain Medicine, American Academy of Pain Management, American College of Clinical Pharmacy, American Pharmaceutical Association, American Society of Health-system Pharmacists, New York State Pain Society, and the Northeastern NYS Council of Health-system Pharmacists, among others. Dr. Fudin is an executive editorial advisor for Practical Pain Management, on the editorial board for the Journal of Pharmacy Practice, and section editor, Pain Medicine. In addition, he is a peer-reviewer for Journal of Pharmacy Practice, Journal of Pain and Palliative Care Pharmacotherapy, for the American Society for Pain Management Nursing Guidelines on Monitoring for Opioid-Induced Sedation and Respiratory Depression. Dr. Fudin is the founder/chairman of PROMPT (Professionals for Rational Opioid Monitoring and Pharmacotherapy), an advocate for clinician education, proactive risk stratification, and appropriate therapeutic monitoring. He is a prolific lecturer, writer, and researcher on pain management.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit.
Universal Activity Number: 827-0000-18-005-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-005-074
This activity is approved for 1.0 contact hour of continuing education (which includes 1.0 pharmacology hour) by the American Association of Nurse Practitioners. Activity ID# 18033105. This activity was planned in accordance with AANP Accreditation Standards and Policies.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from Collegium Pharmaceutical, Daiichi Sankyo, Inc., Purdue Pharma L.P., and Salix, as well as consultant fees from BioDelivery Sciences International, Inc., Nektar, PERNIX Therapeutics, and Quest Diagnostics.
Yvonne D’Arcy has received honoraria related to formal advisory activities from Egalet Corporation; editorial support from Pfizer Inc.; as well as speakers’ bureau activities from the American Association of Nurse Practitioners (AANP), Janssen Pharmaceuticals, Inc., and Practicing Clinicians Exchange. She has also received royalties from Springer Publishing Company.
Dr. Jeffrey Fudin has received honoraria related to formal advisory activities from Daiichi Sankyo, Inc., Egalet Corporation, and Quest Diagnostics; speakers’ bureau activities from AstraZeneca and Daiichi Sankyo; as well as consultant fees from Daiichi Sankyo. He owns significant holdings in Rentigate, LLC.
Planning Committee Disclosures
The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from AstraZeneca
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.